Trubrexa NDC 76420-644

NDC codes

FDA NDC Directory

Product NDC (as listed)76420-644Labeler and product segments. Claims need a package NDC.

Product NDC at billing width76420-0644Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
76420-644-32	76420064432	8 POUCH in 1 BOX (76420-644-32) / 4 PATCH in 1 POUCH / 2.7 g in 1 PATCHMarketed from Dec 13, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Trubrexa
Generic name (nonproprietary): lidocaine and capsaicin
Active ingredients: Capsaicin — .00025 g/gLidocaine — .0475 g/g
Dosage form: Patch
Route: Transdermal
Labeler: Asclemed USA, Inc.
Product type: Prescription drug
Marketing category: Unapproved drug (other)
Marketing start: Oct 3, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Amides (Chemical structure)Local Anesthesia (Physiologic effect)
Identifiers: Product ID 76420-644_0c5d5420-c6cf-0d61-e063-6394a90aea41SPL ID 0c5d5420-c6cf-0d61-e063-6394a90aea41SPL set ID dbdf1df3-7289-4165-8815-f664bef82c56RxCUI 2667457UNII S07O44R1ZM, 98PI200987
Pharmacologic class: Amide Local Anesthetic; Antiarrhythmic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Transdermal products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N476420064432 followed by a unit qualifier and the quantity

Package 76420-0644-32. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 12, 2023.

Indications (excerpt from the label)

1. INDICATIONS & USAGE Trubrexa TM Transdermal Patch is indicated in adults over the age of 12 years old for the treatment of acute and chronic pain in muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, and more.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)